BridgeBio Pharma LLC - 11 Aug 2025 SCHEDULE 13D Report for BridgeBio Oncology Therapeutics, Inc. Common Stock, $0.0001 par value (HLXB)

Filing Manager
BridgeBio Pharma LLC
Reporting Manager
BridgeBio Pharma LLC
Security
BridgeBio Oncology Therapeutics, Inc. Common Stock, $0.0001 par value
Symbol
HLXB
Shares outstanding
79,306,023 shares
Disclosed Ownership
13,878,554 shares
Ownership
18%
Form type
SCHEDULE 13D
Filing time
18 Aug 2025, 17:41:28 UTC
Date of event
11 Aug 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"BridgeBio Pharma LLC disclosed 18% ownership in BridgeBio Oncology Therapeutics, Inc. Common Stock, $0.0001 par value (HLXB) on 11 Aug 2025."

Quick Takeaways

  • BridgeBio Pharma LLC filed SCHEDULE 13D for BridgeBio Oncology Therapeutics, Inc. Common Stock, $0.0001 par value (HLXB).
  • Disclosed ownership: 18%.
  • Date of event: 11 Aug 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 18 Aug 2025, 17:41.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BridgeBio Pharma LLC 18% 13,878,554 13,878,554 0 /s/ Neil Kumar Neil Kumar, Chief Executive Officer 0002076615
BridgeBio Pharma, Inc. 18% 13,878,554 13,878,554 0 /s/ Neil Kumar Neil Kumar, Chief Executive Officer 0001743881

Sponsored